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Abstract
Background: Recently developed immunohistochemical markers have revolutionised the classification of
gastrointestinal stromal tumours (GISTs) whilst tyrosine kinase inhibitors (imatinib) have had a significant impact on
the treatment of advanced tumours. We review the clinicopathological features of previously resected
mesenchymal tumours of the gastrointestinal tract in our institution to 1) reclassify the histological diagnosis of
those stained prior to c-kit availability; 2) perform survival analysis to identify prognostic factors, and 3) to consider
the implications for patients.
Methods: Clinicopathological records of patients with a diagnosis of mesenchymal tumours treated between May
1992 and April 2007 were reviewed.
Results: 82 patients were reviewed. 26 (32%) were reclassified as GISTs following c-kit immunostaining and a
further 14 patients were treated for GIST up to April 2007 (Total: 40 patients; 21 males and 19 females, mean age
67, range 30-92 years). 36 (90%) underwent complete resection. 5-year survival of patients with GIST alone was
80%. Females had a better median survival (M: F 43 months: 73 months).
Conclusions: The availability of c-kit staining allowed 32% of previously diagnosed mesenchymal tumours to be
reclassified as GISTs. This may have implications for the follow-up of patients diagnosed prior to the availability of
this method.
Introduction
Gastrointestinal stromal tumours (GISTs) are the most
common form of mesenchymal (connective tissue)
tumours of the GI tract. They are rare and represent
approximately 0.3-3% of all gastrointestinal tumours [1].
In the last decade studies have discovered that nearly all
GISTs are characterised by the expression of the c-kit
receptor (CD117), as is their cell of origin, the intersti-
tial cell of Cajal [2]. Detection of the c-kit protein in
tumour cells by immunohistochemistry is now the stan-
dard criterion for the diagnosis of GIST. The most
recent estimated incidence of GIST ranges between 1.1-
1.46/100 000 per year based on national epidemiological
studies [3-5].
Surgery is the standard of care for primary disease.
However 40%-90% of surgically resected tumours recur
[6]. Overall survival after surgical resection and clinical
behaviour of GIST are dependent on tumour size and
mitotic count [7,8]. All tumours have the potential to
become malignant and Fletcher et al [9] proposed a
scheme for defining the risk of aggressive behaviour of
GIST into different classes, based on tumour size and
mitotic count [10,11].
GISTs can occur anywhere in the GI tract, however
most GISTs arise in the stomach or small intestine and
infrequently in the colon or rectum, oesophagus, mesen-
tery, or omentum, [12,13]. Patients may present with
few or no symptoms depending on the size and location
of the tumour mass. Small GISTs (2 cm or less) are
usually asymptomatic and found incidentally during
investigations or surgical procedures for unrelated
causes. Larger GISTs can present with GI bleeding, a
palpable mass, obstruction or abdominal pain.
The aim of our study was to review the clinicopatho-
logical features of previously resected mesenchymal
tumours of the GI tract in our institution in order to 1)
reclassify the histological diagnosis of those stained
prior to c-kit availability, 2) perform survival analysis to
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tions of informing patients of their new diagnosis.
Materials & methods
A retrospective review of casenotes of patients treated
for mesenchymal tumours of the GI tract between May
1992 and April 2007 was performed. The patients’ age,
gender, tumour site and size after resection, date of sur-
gery, extent of surgical resection, risk group according
to the classification proposed by Fletcher et al, the pre-
sence and date of local recurrence or distant metastasis,
and the clinical outcome until last follow-up, including
date of death where appropriate, were recorded. Statisti-
cal analysis was performed using SPSS 12.0 software
(Chicago, IL, USA). Overall actuarial survival was calcu-
lated from the day of surgery until death or the last day
of a patient’s visit to the outpatient clinic. Survival
curves were plotted using Life Tables, and multivariate
analysis performed using Cox regression analysis.
Curves were compared using Lee-Desu statistics or Chi-
Square.
Histopathological re-examination of surgical speci-
mens was carried out by 2 Consultant Histopathologists
(PC/BA) using standard hematoxylin and eosin staining
as well as specific immunohistochemical techniques
allowing the identification of tumour’ss i z ea n dn u m b e r
of mitosis at high-power field (HPF). Mutational analysis
for c-KIT/PDGFRA tyrosine kinase receptor genes was
not performed.
Results
82 specimens previously classified as mesenchymal
tumours of the GI tract between May 1992 and July
2003 were reviewed histologically of which 26 (32%)
were reclassified as GIST following c-kit immunostain-
ing. A further 14 patients were treated for GIST up to
April 2007 following routine c-kit staining, introduced
in our institution in 2003. A total of 40 patient case-
notes were reviewed (21 males and 19 females, mean
age 67, range 30-92 years). There was no significant dif-
ference in measured parameters between the patients
identified retrospectively prior to routine c-kit immu-
nostaining, and those identified after its routine adop-
tion. At time of study 18 (45%) patients had died, 12
(30%) were lost to follow up.
Tumours were located in the stomach, small bowel,
large bowel and retroperitoneum in 24, 7, 5 and 4 cases
respectively. Using the “risk of aggressive behavior” clas-
sification proposed by Fletcher et al tumours were clas-
sified as very low (6/40), low (9/40), intermediate (6/40)
and high-risk (19/40). Four patients had separate pri-
mary malignancies at presentation (rectal 1, stomach 2,
sigmoid 1) with the GIST tumour resected as an inci-
dental finding. 3 patients went on to develop separate
primary tumours following complete resection of GIST
(colorectal 1, ovary 1, bladder 1).
Thirty-six patients (90%) underwent complete resec-
tion. Three (7.5%) had incomplete resection due to
degree of local invasion, all of which were high risk
GISTs. 1 patient had unresectable disease and under-
went chemotherapy. The 5 year overall survival was 42%
with a median survival of 46 months. The 5 year survi-
val of patients with GIST alone irrespective of complete
resection was 80%. The presence of separate malignancy
significantly decreased 5 year survival from 50% to 13%
(median survival from 100 months to 32 months) which
reached statistical significance (p = 0.041) (Figure 1).
Complete resection of GIST in these patients did not
affect 5 year survival. Median survival after complete
and incomplete resection for patients with GIST alone
was 74 months versus 11 months respectively. High-risk
tumours had a shorter survival than low and very low
risk tumours (93 months versus 43 months). There was
no statistically significant difference in survival by the
location of tumour. Females had a better median survi-
val than males both overall (median survival 73 months
versus 43 months) and in the patients without separate
malignancy (median survival 73 months versus 37
months). Multivariate analysis identified complete resec-
tion and sex as the most important positive prognostic
factors, and the presence of separate malignancy as the
most important negative prognostic factor for survival.
Of the 26 patients who were reclassified as having
GISTs, 16 have died and 10 were lost to follow up.
Discussion
I nt h i ss t u d yw eh a v ed e m o n s t r a t e dt h a tat h i r do f
patients previously diagnosed with mesenchymal
tumours of the gastrointestinal tract treated before the
advent of c-kit immunostaining were reclassified as
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Figure 1 Life Table showing survival by separate malignancy.
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with c-kit.
Radical surgery to achieve complete resection remains
the treatment of choice. The aim of treatment for
GISTs identified with c-kit immunostaining, and
tumours treated pre c-kit staining as mesenchymal
tumours of the GI tract, remains complete resection.
Therefore in our study management of the patients trea-
ted for GIST pre and post c-kit staining was the same.
Previous studies have reported 5 year survival following
complete resection between 35-75% [8,10,14-16]. Our
findings suggest even higher 5 year survival rates can be
achieved. Treatment may be improved by neoadjuvant
or adjuvant imatinib therapy although its potential role
for large or incompletely resected tumours is yet to be
confirmed [17,18]. Imatinib has been shown to be effec-
tive in locally advanced and irresectable or metastatic
GISTs [19,20] and its use is now recommended in these
patients [21]. No patients in our study were eligible for
imatinib therapy.
We found no significant correlation between site of
GIST and survival. Miettinen et al [22] have suggested
t h a tg a s t r i cG I S T sh a v eam o r ef a v o u r a b l ep r o g n o s i s
than intestinal ones with similar histological parameters.
They proposed a different classification of GISTs into 8
subgroups in relation to size and mitotic rate in order
to better define the rate of metastases in GISTs at dif-
ferent sites. Survival analysis in our population of GISTs
according to Miettinen’s classification are summarised
in Table 1. In the less aggressive histological groups gas-
tric GISTs had an overall improved median survival
when compared to small bowel GISTs, however the
improved survival was reversed in the more aggressive
histological groups. More recently Tryggvason et al con-
firmed with their series that nongastric GISTs had a
clearly higher risk of malignant behaviour than gastric
GISTs [4].
We demonstrated a survival benefit in females in both
univariate and multivariate analysis. Keun Park et al [23]
have also recently found a survival advantage in females
but only in univariate analysis. Comparison of the two
groups in our study did not reveal any obvious con-
founding factors, however further analysis with larger
numbers are required to reveal any statistical signifi-
cance to this finding.
The optimal follow-up protocol for resected GISTs
has not been firmly established. Recurrence appears to
be possible even after many years and may be of slow
onset. GISTs are resistant to conventional chemotherapy
with a poor response rate (7-20%), and short response
duration (1-4 months) [24]. Imatinib is effective therapy
for patients with advanced metastatic or unresectable
GIST and its use has significantly changed the manage-
ment and prognosis for these patients [20,21]. Keun
Park et al [23] showed that adjuvant imatinib for pri-
mary resected intermediate and high-risk GISTs signifi-
cantly improved recurrence-free survival, and more
recently DeMatteo et al [25] confirmed, following a ran-
domised, double-blind, placebo-controlled trial, that
imatinib improves recurrence-free survival following
complete resection of GISTs.
Some clear recommendations of management of such
retrospectively identified cases would be of value. The
question arises as to whether patients previously diag-
nosed with mesenchymal tumours should now have
their diagnosis reviewed with the aim of identifying
patients who may be at risk of recurrence and therefore
may benefit from follow up with a view to earlier diag-
nosis and further treatment. Given the time for which c-
kit has now been available and in regular use it is likely
that such patients have either succumbed to recurrence
of the disease or are free and cured with little affect on
their prognosis. However this data would be important
to further elucidate this as well as the natural history
and progression of such tumours, and the impact that
c-kit has had on overall prognosis of patients suffering
from GIST.
Conclusions
The wide spectrum of histological terms that have been
used in the past to identify GIST has made definition of
its real incidence and survival difficult. Our study shows
that approximately 1/3 of previously diagnosed
mesenchymal tumours of the gastrointestinal tract could
now be reclassified as GISTs. We confirm that the
groups of risk of aggressive behaviour defined by
Fletcher et al are significantly related to prognosis, with
the low and very low risk category having improved
median survival compared to the high risk group. Com-
plete resection remains the most important prognostic
factor and we have demonstrated that an 80% 5 year
Table 1 Median survival in GISTs of stomach and small
intestine by tumours grouped by mitotic rate and
tumour size as proposed by Miettinen et al
21 (n = 40)
Tumour parameters Median survival (months)
Group Size Mitotic rate Gastric Small bowel Other
1 ≤2c m ≤5 per 50 HPFs
2> 2 ≤5c m ≤5 per 50 HPFs
3a >5≤10 cm ≤5 per 50 HPFs
3b >10 cm ≤5 per 50 HPFs
4 ≤2 cm >5 per 50 HPFs
5> 2 ≤5 cm >5 per 50 HPFs
6a >5≤10 cm >5 per 50 HPFs
6b >10 cm >5 per 50 HPFs
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advent of new therapies may have implications for
further possible treatment in patients with advanced or
recurrent disease. This therefore raises the question as
to whether the diagnosis of all previously undefined
mesenchymal tumours of the GI tract where c-kit
immunostaining was not performed should be revised
and patients with confirmed GISTs contacted with a
view to further follow up.
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